The US-China Business Council (USCBC) represents approximately 200 member companies engaged in business across all industries and sectors in China, including manufacturers and marketers of pharmaceutical products. Our companies appreciate efforts by the China Food and Drug Administration (CFDA) to ensure the availability of high-quality, innovative drugs in China, and appreciate the opportunity to provide comments on the CFDA draft Decision on Adjusting Administrative Management for Drug Import Registrations (“draft for comment”), as published on March 17, 2017.
Read the full letter HERE.
